Premium
ECT beyond unipolar major depression: systematic review and meta‐analysis of electroconvulsive therapy in bipolar depression
Author(s) -
Bahji A.,
Hawken E. R.,
Sepehry A. A.,
Cabrera C. A.,
Vazquez G.
Publication year - 2019
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/acps.12994
Subject(s) - electroconvulsive therapy , meta analysis , depression (economics) , major depressive disorder , bipolar disorder , medicine , psychiatry , psychology , refractory (planetary science) , clinical psychology , lithium (medication) , cognition , physics , astrobiology , economics , macroeconomics
Objective In this systematic review and meta‐analysis, the response, remission, and speed of response in adults with major depressive disorder ( MDD ) and bipolar disorder in depressive episode ( BDD ) receiving an acute course of electroconvulsive therapy ( ECT ) were quantitatively analyzed. Methods Using the Preferred Reporting Items for Systematic Reviews and Meta‐analysis guidelines, 1660 citations were identified through five electronic databases. Nineteen articles met final inclusion criteria for meta‐analysis. Results The pooled response and remission rates with ECT in MDD were 74.2% ( n = 1246/1680) and 52.3% ( n = 850/1626), respectively. In BDD , they were 77.1% ( n = 437/567) and 52.3% ( n = 275/377), respectively. Although response rates to ECT were statistically higher in BDD ( OR = 0.73, 95% CI : 0.56–0.95, P = 0.02), remission rates were similar ( OR = 0.91, 95% CI : 0.65–1.26, P = 0.56). Individuals with BDD vs. MDD required fewer number of ECT sessions to achieve response ( SMD = −0.23, 95% CI : −0.44 to −0.023, P = 0.03). There were no significant moderator effects identified. Conclusion Response rates and speed of response are higher in individuals with BDD ; however, remission rates are equivalent. These findings support increased utilization of ECT in individuals with treatment‐refractory BDD .